About Hyacinths Pharma Private Limited
Data last updated:
Hyacinths Pharma Private Limited was a private limited company based in Hyderabad, Telangana, India, operated as a subsidiary of Aurobindo Pharma Ltd. The company has been amalgamated - it was merged with another entity and no longer exists as a separate legal entity. It operated in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 23 July 2010.
The company was registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24232TG2010PTC069638. Its GSTIN is 37AACCH4828E1ZO (Andhra Pradesh). The company held 2 GST registrations, of which 1 is active.
The company had an authorised share capital of ₹35 Cr and a paid-up capital of ₹32.5 Cr. It was led by directors including Satyanarayana Reddy Karri (Whole-Time Director) and Nityananda Reddy Kambam.
Its last annual general meeting (AGM) was held on 24 August 2020, and its latest financial statements are for the year ended 31 March 2020. The registered office was at Plot No.2 Maitrivihar Ameerpet, Hyderabad, Telangana, India – 500038.
The company had about 23 employees on its provident fund (EPFO) records before it was dissolved.
The company was associated with 1 brand: Aurobindo Pharma. The company has 7 deals on record (3 funding rounds, 2 rights issues, 2 secondary share transfers), with disclosed funding of ₹16.72 Cr; the latest was in June 2018.
The last known website on record is aurobindo.com.
Company details
CIN history
Hyacinths Pharma has one previous CIN (Corporate Identification Number): U24232AP2010PTC069638. The current CIN is U24232TG2010PTC069638, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24232TG2010PTC069638 | Current |
| U24232AP2010PTC069638 | Previous |
Contact details
Hyacinths Pharma Private Limited's registered office is in Hyderabad, Telangana. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Social Media
- Registered AddressPlot No.2 Maitrivihar Ameerpet, Hyderabad, Telangana, India – 500038
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Hyacinths Pharma Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Hyacinths Pharma operates one associated brand: Aurobindo Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Generic biocatalytic solutions are provided for pharmaceutical applications. | aurobindo.com |
Business activity
The main business activity of Hyacinths Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
Financials of Hyacinths Pharma Private Limited
FY 2020 filings availableFinancial Statement Summary
| Metrics | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 | FY 2014-15 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | |||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | |||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 | FY 2014-15 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | |||||
| Net Profit Margin | |||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Hyacinths Pharma Private Limited, buy the company report.
Board of directors of Hyacinths Pharma Private Limited
Hyacinths Pharma has 3 current directors and 6 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Nityananda Reddy Kambam Also directs: Aurobindo Pharma Ltd, Aurobindo Antibiotics Private Limited, Apl Healthcare Limited and 5 more | Director | 16 Sep 2013 | 13 Years 1 Months | As last reported |
| Satyanarayana Reddy Karri | Whole-Time Director | 23 May 2019 | 7 Years 5 Months | As last reported |
| Venkateswararao Kondreddy Also directs: Raidurgam Developers Limited, Epravinya Solutions LLP | Director | 18 Sep 2017 | 9 Years 1 Months | As last reported |
Auditor
Hyacinths Pharma Private Limited is audited by G PAVAN KUMAR & ASSOCIATES for the financial year 2018.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| G PAVAN KUMAR & ASSOCIATES | FY 2018 | 015343S |
Shareholding
The shareholding of Hyacinths Pharma Private Limited is on record for 3 financial years, the latest being FY 2018, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|
| Promoters | |||
| Domestic institutional investors (DII) | |||
| Foreign institutional investors (FII) | |||
| Public | |||
| Others |
To see the full shareholding pattern of Hyacinths Pharma Private Limited, buy the company report.
Deals & funding
Hyacinths Pharma Private Limited has 7 deals on record (3 funding rounds, 2 rights issues, 2 secondary share transfers), with disclosed funding of ₹16.72 Cr; the latest was in June 2018.
Deals on record (5 of 7)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jun 2018 | Funding round | ₹7 Cr | Investors: Aurobindo Pharma Ltd |
| Apr 2018 | Rights issue | ₹10.55 Cr | Investors: Aurobindo Pharma Ltd |
| Jan 2017 | Rights issue | ₹5.21 Cr | Investors: Aurobindo Pharma Ltd |
| Mar 2014 | Funding round | ₹1.71 Cr | Investors: Aurobindo Pharma Ltd |
| Oct 2013 | Secondary share transfer | Undisclosed | Buyer: Aurobindo Pharma Ltd , an individual Seller: Trident Chemphar Limited , 3 individuals |
To see the full deal history of Hyacinths Pharma Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Hyacinths Pharma Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Hyacinths Pharma Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Hyacinths Pharma Private Limited has a workforce of 23 employees on its EPFO records as of Mar 28, 2024, across 1 active EPFO establishment.
GST
Hyacinths Pharma has 2 GST registrations: 1 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 37AACCH4828E1ZO | Andhra Pradesh | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Hyacinths Pharma Private Limited, buy the company report.
Recent activity
Hyacinths Pharma Private Limited has 9 board changes on record since 2013: 3 appointments and 6 cessations. The latest: Satyanarayana Reddy Karri was appointed as Whole-Time Director on 23 May 2019.
News
Frequently asked questions
Hyacinths Pharma has been "Amalgamated" (merged) as per MCA records. The company was combined with another entity and no longer exists as a separate legal entity. Business activities, if any, continue under the successor entity.
Hyacinths Pharma was a private limited company based in Hyderabad, Telangana, India. The company worked in drug formulation and development, within the pharma industry. It was incorporated on 23 July 2010 and is registered under CIN U24232TG2010PTC069638. The company is recorded as amalgamated in MCA records and no longer exists as a legal entity.
Hyacinths Pharma was incorporated on 23 July 2010. It is registered with the Registrar of Companies, Hyderabad.
Hyacinths Pharma had 3 directors:
- Satyanarayana Reddy Karri - Whole-Time Director
- Nityananda Reddy Kambam - Director
- Venkateswararao Kondreddy - Director
The CIN (Corporate Identification Number) of Hyacinths Pharma is U24232TG2010PTC069638. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
The registered office of Hyacinths Pharma is at Plot No.2 Maitrivihar Ameerpet, Hyderabad, Telangana, India – 500038.
Hyacinths Pharma can be reached through the website aurobindo.com. Its registered office is in Hyderabad, Telangana, India.
The latest financial statements of Hyacinths Pharma on record with the MCA are for the year ended 31 March 2020. Its last annual general meeting was held on 24 August 2020. Year-wise statements from 2015 are in the company report.
The GSTIN of Hyacinths Pharma is 37AACCH4828E1ZO, registered in Andhra Pradesh. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
Hyacinths Pharma operated in the pharma industry, in the drug formulation and development segment.